Company intelligence / Profile preview

CaRACS

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

CaRACS is a biotechnology company focused on developing innovative cell therapies for cardiovascular diseases, specifically targeting cardiac fibrosis. The company utilizes Chimeric Antigen Receptor (CAR) T-cell technology to identify and eliminate activated fibroblasts that contribute to heart tissue scarring after injury. By targeting Fibroblast Activation Protein (FAP), CaRACS aims to reverse fibrosis and restore heart function in patients suffering from acute coronary syndrome and chronic heart failure. This approach represents a novel application of oncology-derived cell therapy techniques to the field of regenerative cardiology.

Therapeutic areas: Cardiovascular
Modalities: Cell therapyCAR-T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on CaRACS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CaRACS.

Explore the full profile